Gainesville, Florida -- Derma Sciences has begun selling Bioguard barrier dressings -- the first wound dressing to use proprietary non-leaching Nimbus biocide technology from Quick-Med Technologies Inc. of Gainesville, Florida. The new biocide offers surgeons, woundcare clinicians, infection-control experts and primary care doctors "an important new weapon against the transmission of such virulent bacteria as Methicillin-resistant Staphylococcus aureus (MRSA)," Quick-Med claimed, in a 26 June release.
Nimbus, which was approved by the US Food and Drug Administration in late February 2009, is the first non-leaching antimicrobial available in a wound dressing, said Quick-Med.
The system uses a polyquaternary biocide, irreversibly bonded to any of several materials such as polyurethane, cotton or rayon, for use in woundcare products.
The company says that, because of the bonding, the material is unlike other antimicrobial agents that are released into the wound. Hence Nimbus does not interfere with wound healing and does not result in bacterial resistance.
Ed Quilty, ceo of Derma Sciences, said:"We expect Bioguard to quickly become one of our most successful new brands to enter into the $14 billion dollar global woundcare market."
Quick-Med said that Nimbus is non-toxic, long-lasting and not blocked by organics such as blood, urine and perspiration. The company has been allowed to label the product to say that various organisms such as MRSA, VRE, Pseudomonas aeruginosa and Escherichia coli are killed at levels exceeding 99.999%.
"Traditional wound dressings absorb fluid from the wound and act as a great incubator for bacteria that are shed back into the wound," said Gregory Schultz, Professor, Institute for Wound Research at the University of Florida and Past President of the Wound Healing Society. "This Nimbus is the first bound, antimicrobial material. Rather than delivering an antimicrobial into the wound, it creates a barrier that won't allow bacteria to penetrate the dressing or grow in the wound fluid."